IMNN: Results from OVATION 2 Study in Mid-2024… [Yahoo! Finance]
Imunon, Inc. (IMNN)
Company Research
Source: Yahoo! Finance
Imunon, Inc. (NASDAQ:IMNN) is currently conducting the Phase 1/2 OVATION 2 trial of IMNN-001, the company's IL-12 gene-mediated immunotherapy that is based on the TheraPlas™ technology. The OVATION 2 study is evaluating the dosing, safety, efficacy, and biological activity of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Full enrollment of 110 patients for the trial was reached in September 2022. Being a Phase 1/2 trial, it is not powered for significance. It was designed with an 80% confidence interval to show an approximately 33% improvement in PFS when comparing the treatment arm (NACT+IMNN-001) with the control arm (NACT only). Interim data from the intent-to-treat population show efficacy trends in PFS, with a delay in disease progression in the treatment arm of approximately 33% compared with the control arm. Preliminary OS data showed a s
Show less
Read more
Impact Snapshot
Event Time:
IMNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNN alerts
High impacting Imunon, Inc. news events
Weekly update
A roundup of the hottest topics
IMNN
News
- First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical TrialGlobeNewswire
- Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingGlobeNewswire
- Imunon, Inc. (NASDAQ: IMNN) had its price target lowered by analysts at HC Wainwright from $13.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
IMNN
Sec Filings
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- IMNN's page on the SEC website